Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (GI005)
Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (GI005)
Trial Category:
Gastrointestinal
Phase
II
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
